PNAS researchers say a peptide they developed as a possible Alzheimer's treatment turns out to exist naturally in human blood.
Recap by typeshit. Post by PNASNews on X.
The review looks at concerns about misuse as demand for GLP-1 drugs grows, and points to how little evidence guides their use beyond approved conditions.
Researchers found self-reported GLP-1 use climbed from March 2024 to October 2025, mostly for weight loss, through channels insurance data may not capture.
The study is looking for women with hot flashes and night sweats and a BMI above 30. Mayo Clinic has the full eligibility rules and how to sign up.
A matched cohort study in Inflammatory Bowel Diseases found remission odds nearly six times higher on GLP-1 drugs, and weight loss alone didn't explain it.
Part of his GLP-1 series, Krittanawong looks at research suggesting these drugs may protect the kidneys beyond blood sugar and weight.
Health authorities are warning people off unregulated peptides as emergency departments report a rise in severe allergic reactions.
Loading…